{"disease":{"id":"non-squamous-non-small-cell-lung-cancer","name":"non squamous non small cell lung cancer"},"drugs":{"marketed":[{"drug_id":"bevacizumab-maly","indication_name":"Non-Squamous Non-Small Cell Lung Cancer - First Line","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"telisotuzumab","indication_name":"locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."},{"drug_id":"zongertinib","indication_name":"unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hernexeos","generic_name":"ZONGERTINIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Hernexeos works by blocking the HER2 tyrosine kinase domain, which is a protein that helps cancer cells grow and divide."},{"drug_id":"zongertinib","indication_name":"unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hernexeos","generic_name":"ZONGERTINIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Hernexeos works by blocking the HER2 tyrosine kinase domain, which is a protein that helps cancer cells grow and divide."}],"pipeline":[{"drug_id":"pf-06439535-cn","indication_name":"Advanced non-squamous non-small-cell lung cancer (NSCLC)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06439535 (CN)","generic_name":"pf-06439535-cn","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Not publicly disclosed; presumed to be VEGF pathway or related angiogenic target based on clinical trial design","drug_class":"Selective pathway inhibitor; presumed anti-angiogenic agent","quality_score":null,"revenue":null,"mechanism":"Selective inhibitor blocking proteins that drive abnormal cell growth and division in cancer cells."}],"offLabel":[],"totalMarketed":4,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT02008227","title":"A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1225,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04267848","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1210,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01827852","title":"AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung","phase":"","overall_status":"COMPLETED","enrollment_count":1107,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06417008","title":"A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1080,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT01244191","title":"Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1048,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT06627647","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":878,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07485166","title":"Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":810,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04795245","title":"Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":805,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06847334","title":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":772,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT03829319","title":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":761,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04750083","title":"HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"Taizhou Hanzhong biomedical co. LTD","has_results":false},{"nct_id":"NCT03329911","title":"A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":651,"lead_sponsor_name":"Bio-Thera Solutions","has_results":true},{"nct_id":"NCT04416035","title":"A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":608,"lead_sponsor_name":"Zhejiang Teruisi Pharmaceutical Inc.","has_results":false},{"nct_id":"NCT03793179","title":"Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02264990","title":"Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":595,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05338970","title":"HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":586,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT04205812","title":"Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":583,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT01673867","title":"Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":582,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03906071","title":"Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":577,"lead_sponsor_name":"Mirati Therapeutics Inc.","has_results":true},{"nct_id":"NCT02409342","title":"A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05132413","title":"A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":561,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03169335","title":"Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":535,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05318443","title":"A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":512,"lead_sponsor_name":"Shanghai Institute Of Biological Products","has_results":false},{"nct_id":"NCT07383116","title":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Shanghai Huaota Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03802240","title":"Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":492,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT01351415","title":"A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":485,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04179890","title":"The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib","phase":"","overall_status":"COMPLETED","enrollment_count":462,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06396065","title":"Phase III Study of AK112 for NSCLC Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":420,"lead_sponsor_name":"Summit Therapeutics","has_results":false},{"nct_id":"NCT06505837","title":"JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":395,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT06416410","title":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"Allist Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02193282","title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":390,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04439890","title":"A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":369,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT06311721","title":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":315,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04181060","title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01893268","title":"An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":279,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03468426","title":"A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06491862","title":"RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05652868","title":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Mythic Therapeutics","has_results":false},{"nct_id":"NCT01310036","title":"A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04032704","title":"A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":205,"lead_sponsor_name":"Seagen Inc.","has_results":true},{"nct_id":"NCT04716933","title":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06961188","title":"Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT00760929","title":"A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":171,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04063449","title":"Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC","phase":"NA","overall_status":"UNKNOWN","enrollment_count":170,"lead_sponsor_name":"Dong Wang","has_results":false},{"nct_id":"NCT07122687","title":"IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT00152477","title":"A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"UCB Pharma","has_results":true},{"nct_id":"NCT06430866","title":"Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":163,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT04262856","title":"Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}